Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more

Recent & Breaking News (NDAQ:APLS)

ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

TheNewsWire September 10, 2023

ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

PR Newswire September 9, 2023

APELLIS PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS

PR Newswire September 8, 2023

APLS Investors Have Opportunity to Lead Apellis Pharmaceuticals, Inc. Securities Fraud Lawsuit

PR Newswire September 8, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 8, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

Newsfile September 7, 2023

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc.(APLS) Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire September 7, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 7, 2023

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Apellis Pharmaceuticals, Inc. - APLS

PR Newswire September 6, 2023

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

Newsfile September 6, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 6, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)

PR Newswire September 6, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 6, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

PR Newswire September 5, 2023

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire September 5, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm

Accesswire September 5, 2023

ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

TheNewsWire September 4, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire September 4, 2023

APLS INVESTOR NOTICE: Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Newsfile September 3, 2023

ROSEN, LEADING INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

TheNewsWire September 2, 2023